Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective
Abstract
Share and Cite
Bebb, D.G.; Agulnik, J.; Albadine, R.; Banerji, S.; Bigras, G.; Butts, C.; Couture, C.; Cutz, J.C.; Desmeules, P.; Ionescu, D.N.; et al. Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective. Curr. Oncol. 2019, 26, 551-557. https://doi.org/10.3747/co.26.5137
Bebb DG, Agulnik J, Albadine R, Banerji S, Bigras G, Butts C, Couture C, Cutz JC, Desmeules P, Ionescu DN, et al. Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective. Current Oncology. 2019; 26(4):551-557. https://doi.org/10.3747/co.26.5137
Chicago/Turabian StyleBebb, D.G., J. Agulnik, R. Albadine, S. Banerji, G. Bigras, C. Butts, C. Couture, J.C. Cutz, P. Desmeules, D.N. Ionescu, and et al. 2019. "Crizotinib Inhibition of ROS1-Positive Tumours in Advanced Non-Small-Cell Lung Cancer: A Canadian Perspective" Current Oncology 26, no. 4: 551-557. https://doi.org/10.3747/co.26.5137